Patient engagement is the active involvement of patients in the design, development, and evaluation of healthcare strategies, including clinical trials and evidence generation.

Patient-reported outcomes (PROs) are direct reports from patients about their symptoms, functioning, or quality of life, without interpretation by clinicians.

A Payer Influencing Key Opinion Leader (PIKOL) is a key influencer of healthcare policy and reimbursement decisions.

Peer-to-peer engagement involves direct scientific exchange between healthcare professionals, often facilitated by field medical teams such as medical science liaisons (MSLs).

Pharmacovigilance is the science and practice of monitoring, detecting, assessing, and preventing adverse effects or other drug-related problems after a product has entered the market.

A placebo-controlled study is a clinical trial in which the effects of an investigational treatment are compared against an inactive substance that mimics the treatment but has no therapeutic effect.

Population health impact refers to the measurable effect of a therapy or intervention on the overall health outcomes of a defined population.

Predictive analytics uses historical and real-time data to forecast future outcomes, helping guide strategic decisions in clinical development and market access.

In epidemiology, prevalence describes the proportion of a population that has a disease at a specific point in time.

Price benchmarking is the process of comparing the price of a pharmaceutical product to similar therapies across markets to inform pricing strategy and negotiation.

Price potential refers to the estimated price a pharmaceutical product could reasonably achieve based on its clinical value, competitive positioning, and payer willingness to pay.

Pricing and reimbursement refers to the processes by which a pharmaceutical product is assigned a price and granted coverage or funding by healthcare payers.

Product value communication is the strategic process of articulating the unique attributes, patient benefits, and economic value of a drug or therapy.

A publication strategy is a structured plan for disseminating scientific and clinical data through peer-reviewed journals and congresses to support a product’s development and value story.

Publication type categorizes scientific articles by format and purpose, influencing how they are perceived and weighted in bibliometric analysis.

A publishing plan is a strategic roadmap for disseminating clinical, real-world, and health economic data through peer-reviewed journals and scientific platforms.

Qualitative research is a method used to gather non-numerical insights into stakeholder behaviors, perceptions, motivations, and decision-making processes.

Quantitative research involves the collection and statistical analysis of numerical data to identify patterns, test hypotheses, or measure outcomes.

Real-world data (RWD) refers to health-related data collected outside of traditional clinical trials, used to understand how treatments perform in routine clinical practice.

Real-world effectiveness measures how well a treatment performs in routine clinical practice, outside the controlled environment of clinical trials.

Real-world evidence (RWE) refers to clinical insights derived from the analysis of real-world data (RWD), used to evaluate how treatments perform outside of controlled trial settings.

Regulatory strategy is the plan that guides how a pharmaceutical company will navigate requirements for product approval, labeling, and post-marketing commitments.

A regulatory submission is a comprehensive dossier submitted to health authorities to seek approval for a new drug, indication, or formulation.

The reimbursement landscape refers to the policies, payer expectations, and pricing mechanisms that influence whether and how a product will be funded.

Research and development (R&D) is the process of discovering, designing, and testing new pharmaceutical products to advance medical science and improve patient outcomes.

A Rising Star is a medical or scientific professional in the early to mid-stage of their career who demonstrates potential to become a prominent and influential voice in their field.

Rising Star identification is the process of recognizing early-career experts who are gaining influence and making significant contributions in their field.

At VISFO, a Rising Star impact factor is a proprietary bibliometric-based calculation used to identify and rank future Key Opinion Leaders (KOLs).

A risk factor is any attribute, condition, or behavior that increases the likelihood of developing a disease or experiencing an adverse health outcome.

A risk-sharing agreement is a contractual arrangement in which a pharmaceutical company and payer share financial or clinical risk based on treatment outcomes.

Scientific exchange refers to non-promotional, data-driven communication between a pharmaceutical company and healthcare professionals, focused on advancing clinical understanding.

Scientific landscaping is the systematic analysis of published and emerging research to identify trends, gaps, and strategic opportunities within a therapeutic area.

Sentiment analysis is the use of natural language processing (NLP) and machine learning to evaluate the tone and emotional context of written or spoken content.

Share of voice (SOV) is a metric that measures the proportion of total mentions or visibility a product, brand, or company receives within a defined competitive or thematic space.

Site ranking is the process of evaluating and ordering clinical trial sites based on performance metrics such as patient enrollment, data quality, and regulatory compliance.

Stakeholder mapping is the creation of a comprehensive overview of key stakeholders relevant to a particular therapeutic area, indication, condition or product.

Stakeholder segmentation is the process of categorizing healthcare stakeholders into groups based on shared attributes, interests, or behaviors to tailor engagement strategies.

Stakeholder sentiment refers to the tone and attitude expressed by healthcare professionals, payers, patients, or other influencers toward a product, topic, or company.

Strategic publication planning is the process of aligning scientific communication efforts with product goals, evidence timelines, and stakeholder needs.

A surrogate endpoint is a biomarker or intermediate measure used in clinical trials as a substitute for a direct measure of clinical benefit.

A target product profile (TPP) outlines the ideal characteristics of a pharmaceutical product to guide development and align stakeholder expectations.

Territorial lines refer to the geographic or operational boundaries used to structure stakeholder engagement and field team activities.

A thought leader is an individual widely recognized for their expertise, original ideas, and ability to influence thinking and practice within a specific field.

Time-to-peak-uptake is the period it takes after launch for a product to reach its maximum level of market adoption.

Top 100 KOL refers to a subset of highly influential experts within a specific therapeutic area, identified through quantitative and qualitative analysis.

The treatment landscape describes the full range of available therapies and treatment strategies for a particular disease or condition.

Trial site analysis is the evaluation of potential clinical trial sites to optimize study performance.

Unbranded engagement involves scientific or educational communication that does not promote a specific product but builds awareness around a disease, unmet need, or treatment approach.

Unmet need refers to a gap in medical care where current treatment options are inadequate, unavailable, or ineffective for a specific patient population or condition.

User-defined data updates allow users to control how frequently their dashboards and datasets refresh, enabling continuous tracking of dynamic metrics.

A value proposition is a clear, evidence-based summary of the benefits a product offers to patients, providers, and payers.

Voice of the customer (VoC) refers to insights gathered from stakeholders that reflect their needs, expectations, and experiences with a product or therapeutic area.

Willingness to pay refers to the maximum amount a healthcare payer, provider, or system is prepared to spend for a treatment, based on its perceived value and health outcomes.

Workflow integration refers to the alignment of a product or tool with the routines and systems used by healthcare professionals in clinical practice.